Bio Green Med Solution, Inc.
BGMS Healthcare Biotechnology
Bio Green Med Solution, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747,000.00, up 1,637.2% from fiscal 2024. In the quarter to June 2026, revenue grew 3,260.0%, EPS grew 91.8% and free cash flow grew 66.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow BGMS
Bio Green Med Solution, Inc. (BGMS) Altman Z-score
Bio Green Med Solution, Inc.'s Altman Z-score for fiscal 2025 is −78.86, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −78.86 | 81.66 |
| FY2024 | −160.52 | (83.00) |
| FY2023 | −77.52 | (53.32) |
| FY2018 | −24.20 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.60 | — | 0.72 | |
| Retained earnings / total assets | (55.52) | — | −77.72 | |
| EBIT / total assets | (1.03) | — | −3.40 | |
| Market value of equity / total liabilities | 2.41 | — | 1.44 | |
| Sales / total assets | 0.09 | — | 0.09 | |
| Altman Z-score | Distress zone | −78.86 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −178.61 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| CDIO Cardio Diagnostics Holdings, Inc. compare | −3.6× |
| CELZ Creative Medical Technology Holdings, Inc. compare | −4.3× |
| IMNN Imunon, Inc. compare | −12.5× |
| PULM Pulmatrix, Inc. compare | −27.9× |
| CANF Can-Fite Biopharma Ltd compare | −28.0× |
| BGMS Bio Green Med Solution, Inc. | −78.9× |
| ORGS Orgenesis Inc. compare | −352× |
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | — |
| NRSN NeuroSense Therapeutics Ltd. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets